Phase II Study to Evaluate the Role of Bortezomib in the Management of Relapsed Acute Promyelocytic Leukemia
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Bortezomib (Primary) ; Arsenic trioxide
- Indications Acute promyelocytic leukaemia
- Focus Adverse reactions
- Acronyms PIAPL
- 01 Oct 2013 New trial record